ISPOR Announces Appointment of New Associate Chief Science Officer

Published Jan 22, 2018
Lucinda Strycker Orsini Joins the Society in New Science Role   Lawrenceville, NJ, USA—January 22, 2018—ISPOR, the professional society for health economics and outcomes research, announced today that Lucinda Strycker Orsini, DPM, MPH has joined the Society’s leadership team in the role of Associate Chief Science Officer. In this new role, Dr. Orsini will work closely with ISPOR’s Chief Science Officer, Richard J. Willke, PhD to direct, lead, and execute strategic initiatives related to research, scientific, and content priorities to advance the Society’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. Dr. Orsini brings significant experience in the field of health economics and outcomes research (HEOR) to her new role at ISPOR. Her most recent position was as Vice President at Parexel where she led an HEOR team that provided a wide range of consulting services. Previously, Dr. Orsini worked at Bristol-Myers Squibb since 2005 where she held a variety of positions with increasing responsibility. Her most recent position at Bristol-Myers Squibb was Group Director in the worldwide HEOR group supporting oncology/immuno-oncology products. Previous to this, she was at Thomson Medstat where she worked extensively with real-world data studies. Dr. Orsini has her Doctor of Podiatric Medicine from Temple University, Master of Public Health from the Harvard T.H. Chan School of Public Health, and Bachelor of Science from Cornell University. “We are very excited to announce the appointment of Lucinda Orsini into the new role of Associate Chief Science Officer,” stated ISPOR’s Chief Science Officer Richard J. Willke, PhD. “Lucinda brings a wealth of experience in HEOR to her new role and will help advance the many strategic initiatives at the Society.”

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg    

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×